The TIGIT protein has turned into an arms race for Big Pharma, with Merck and Roche looking to add their own candidates to checkpoint inhibitor combos. A smaller player in that race, iTeos Therapeutics, is one step behind those big names and is rolling out early data that looks pretty par for the course.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,